SUMMARY Epidermal growth factor (EGF) is localised in man to salivary and Brunner's glands. It is present in large concentrations in saliva and duodenal contents but the mechanisms of its release have been little studied. This study carried out on four groups of healthy subjects was designed to determine the distribution and the release of immunoreactive EGF (IR-EGF) in salivary, gastric, duodenal, and pancreatic secretions. Under basal conditions, the concentrations of IR-EGF in salivary, gastric, duodenal and pancreatic secretions were; 2.7 (0.4), 0.42 (0.12), 21 (5) and 8.5 (1.2) ng/ml, respectively. Chewing of Parafilm* significantly increased salivary but not gastric or duodenal EGF output while atropinisation led to the reduction in basal salivary and duodenal EGF output without affecting the increment in EGF release induced by chewing. Cigarette smoking caused a marked reduction in basal salivary and duodenal EGF output. Infusion of pentagastrin increased salivary and duodenal EGF output and this was blocked by the addition of somatostatin. Injection of secretin lead to an increase in pancreatic output of EGF. We conclude that in man the major sources of EGF are salivary glands, duodenum, and pancreas and that the release of EGF remains under neurohormonal control.
Epidermal growth factor (EGF) originally isolated by Cohen' from the mouse submaxillary glands is a 53 amino acid peptide structurally resembling urogastrone, another peptide isolated from urine.' Urogastrone was discovered after the observation that the extracts of urine from pregnant women had beneficial effect on healing of chronic ulcers in MannWilliamson dogs. 3 Studies on animals showed that EGF, like urogastrone, displays many kinds of biological effects including stimulation of proliferation and differentiation of epithelial and non-epithelial tissues"4, stimulation of DNA synthesis4 through increasing ornithine decarboxylase activity,' protection of the gastroduodenal mucosa against various irritants, enhance-present in human saliva, urine and milk" and to be localised to the submandibular glands, Brunner's glands in the duodenum and the Paneth cells of the small intestine.'``Studies on the distribution of EGF in human gastrointestinal tract have, however, been limited mainly to immunocytochemistry and little information is available regarding the distribution and the release of EGF under various physiological conditions. This study was undertaken to compare the release of immunoreactive EGF (IR-EGF) into the salivary, gastric, duodenal and pancreatic secretions under basal conditions and after neurohormonal stimulation and smoking in healthy subjects.
Methods

SUBJECTS
Male volunteers, aged between 20-24 years (mean age 22) and weighing between 68-77 kg (mean weight 74 kg) entered the study after giving informed consent. All subjects were in good health and without gastro-intestinal disorders. Gastroscopy carried out one week before the start of the study revealed no Release of EG F1 abnormalities or peptic ulceration. None of the subjects showed any abnormalities in the orodental, oropharyngeal and salivary gland areas. The study was approved by the Institutional Human Research Review Committee.
I.XIP RIMI.N INAI DES 1(N Several series of experiments were carried out on four groups (group A, B, C and D) of subjects with five to seven day intervals between tests. Ten subjects (group A) underwent studies with basal secretion and Parafilm chewing without or with atropinisation; 10 subjects (group B) were used for studies with pentagastrin and somatostatin, 10 subjects (group C) were used for studies with cigarette smoking and six others (group D) were used to obtain pure pancreatic juice before and after secretin administration.
On the morning after 12 h fasting period, all subjects refrained from smoking and did not use tooth paste. Double lumen gastroduodenal Dreiling tube with endotracheal cuff was inserted and positioned under fluoroscopic control with the cuff inflated just distally to the pylorus to prevent any escape of gastric juice into the duodenum or any reflux of the duodenal content into the stomach as previously described.1' Subjects were instructed not to swallow throughout the study and saliva, gastric juice and duodenal contents were aspirated and collected in 15 min aliquots. All samples were kept on ice, their volume was measured and 1-2 ml aliquots were taken into plastic tubes with Trasylol (500 IU/l ml), adjusted to pH 70. centrifuged and supernatant frozen at -20(C until radioimmunoassay of EGF. In addition, the amylase concentration in the saliva, acid concentration in the gastric juice and amylise concentration in the duodenal aspirates were determined as described before' " and expressed in outputs per 30 min.
In tests on group A subjects, the salivary gastric and duodenal secretions were collected for a one hour period and then 15 min Parafilm chewing was carried out followed by additional one hour collection period. These tests were repeated after iv injection of atropine ( 1() 0g/kg) after 30 min of basal collection.
In tests of group B subjects, the saliva gastric and duodenal secretions were collected for 30 min and then pentagastrin (2 gg/kg/h) was infused for two h.
After one hour pentagastrin administration, sominatostatin (2.5 gg/kg/h) was added to iv infusion for the period of one hour. In control tests, pentagastrin alone without somatostatin was infused for a two hour period.
In tests on group C subjects, basal collection of the salivary gastric and duodenal secretions was obtainied for one hour and then one cigarette was smoked during each 30 min period wlhile the secretory collection was continued for next one hour period.
In 10 subjects of group D, pure pancreatic juice was obtained by endoscopic cannulation of the papilla of Vater. A side viewing duodenoscope, Olympus model JF-B, was used, through which a sterile Teflon cannula was passed (external diameter 15 mm). Only subjects with a normal retrograde pancreatogram without a separate opening of the duct of Santorini into the duodenum, and with a pancreatic duct system not communicating with the common duct were included into the study. Consequently, a contamination of pancreatic juice with bile was avoided. Tests were done in the early morning after an overnight fast, after local application of 20(% benzocaine (Hurricaine, Bentlich Pharmaceutical, Chicago, Ill.) on the oropharyngeal mucosa. Subjects were allowed to be on the left side to facilitate pooling of the gastric contents in the body of the stomach. Gastric juice was continuously aspirated during endoscopy through an additional tube with a vacuum pump at a negative pressure of about 20 nm Hg. Duodenal content was first aspirated through the Teflon cannula, which was then inserted into the Period wshen parafilm-chewing was performed: tperiod when atropine wats injected; *-significant (p <0.05) decrease helou the value obtained in control tests wsith attropine.
saliva from basal value of about 12-5 (2.6) mlI5 min to 29*0 (3.6) ml/15 min (Table 1) . EGF concentration during chewing tended to decrease but it was not significant.
The concentration (0.42 (0.12) ng/ml) and the output (5-4 (1.2) ng/15 min) of EGF in gastric juice were several times smaller than in saliva ( Table 1) . Chewing of Parafilm, pentagastrin or smoking failed to cause anty alteration of these values in gastric juice suggesting that EGF in the stomach may be produced in negligible amounts or may originate from other sources sutch as salivary glands or duodenum. The concentrations and outputs of EGF in the duodenal cotitents were, respectively, about five and two times higher than in saliva. Chewing tended to increase duodenal EGF outputs but this was not statistically significant.
Injection of atropine ( 10 ,g/kg) caused significant reduction in basal salivary and duodenal but not oastric outtputs of EGF. This reduction was due to the decrease in the volume of saliva and duodenal contents (Table 1) . Chewing in atropinised subjects resulted in the increment in salivary EGF outputs but no changes in EGF outputs were observed in gastric or duodenal contents (Fig. 2) .
Chewing significantly increased salivary amylase outputs and this effect was almost completely aabolished by atropine. No significant alteration in gastric acid or duodenal amylase outputs were observed during chewing but atropine caused significant reduction in gastric acid and duodenal amylase secretion (Table 2) .
After infusion of pentagastrin (at a dose which caused maximal gastric acid output) significant and sustained increase in salivary and duodenal but not gYastric EGF outputs were observed (Fig. 3) . This of 10 tests in 10 healtliy subjects. *Indicates significant increase above t/ie basal value and **indicates significant decrease below t/ie value obtained in tests without atropine. increase in EGF secretion was mainly caused by the rise in the volume of salivary and duodenal secretions. Somatostatin infused at a dose (2.5 1,g/kg/h) which strongly inhibited gastric acid response to pentagastrin, resulted in the decrease in salivary and duodenal secretions to the basal (prepentagastrin) level. No change in gastric EGF outputs were observed in tests with pentagastrin and somatostatin infusion. Pentagastrin infusion induced a significant increase in salivary and duodenal amylase outputs and in gastric acid outputs. Addition of somatostatin resulted in significant decrease in all these secretory parameters to the basal value (Table 2) .
Smoking one cigarette per 30 min resulted in a significant reduction in EGF concentrations and outputs both in saliva and duodenal contents (Fig. 4) . This reduction was pronounced and observed throughout the period of smoking. Table 3 shows the concentrations and outputs of EGF in pancreatic juice obtained during endoscopic cannulation of pancreatic duct before and after injection of secretin. The concentration of EGF in gastr-ic and duodenal secretions. *Indicates sig decrease below the control value obtained in te smoking. Mean (SEM) of 10 tests on 10 h1ealtli
Discussion
This study provides evidence that as salivary glands, the duodenal muco pancreas, are rich sources of IR-EG gastrointestinal tract. Previous studies EGF is localised mainly to salivary
Brunner's glands in the duodenum into saliva.' Our study shows for the first time chewing, activating stimulatory me salivary flow, increases also the output c sensitive to somatostatin which almost completely ty subjets. abolished pentagastrin induced increase in salivary and duodenal EGF. A previous study in man has revealed that pentagastrin stimulates salivary secretion of amylase and that simultaneous administration of somatostatin blocks the effect of pentagastrin on well as the salivary flow but did not reduce the amylase concenisa and the tration.'`Our results with salivary amylase secretion F in human in these tests were similar and they suggest that the showed that mechanism exerted by pentagastrin and somatostatin glands and on EGF release into saliva is different from that and secreted involved in amylase secretion. It is of interest that pentagastrin caused also a marked increase in the that simple EGF in duodenum and somatostatin blocked this ,chanism of effect. This suggests that the control of salivary and )f IR-EGF in duodenal EGF secretion may be similar. This is the first finding suggesting the implication of a hormonal mechanism in the release of salivary and duodenal n pure f EGF. " as well as from the pancreas. Previous studies on animals showed that the pancreas contains as high a concentration of EGF as salivary tissue.' It is likely, therefore, that previously reported' and presently observed high EGF content in the duodenum originates, at least in part, from the pancreas. Our finding of high concentration of IR-EGF in the pancreatic juice collected directly from the pancreatic duct provides an evidence that in man, as in animals, the pancreas is a rich source of EGF and that the release of EGF is stimulated by secretion. The rise in pancreatic EGF output after secretin injection was mainly the result of the increase in pancreatic volume flow and probably represented the 'washout' of the peptide from the pancreas. The role of pancreatic EGF is unknown but previous studies showed that this peptide may contribute to the stimulation of pancreatic secretion' and tissue growth.4"'-4 Whether EGF secreted in the pancreatic juice in large amounts has any protective, ulcer healing or growth promoting action on the duodenal mucosa is unknown but previous observations of increased production of duodenal ulcerations after diversion of pancreatic juice from the duodenum-' suggest that pancreatic EGF may play an important role in the prevention or healing of duodenal ulcerations. growth factor in man. 
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